Evidence map›Paper›PMID 29326917›Full record

ArticleFrontiers in public health2017

Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the

Stefanie J Vaccher, Christopher Gianacas, David J Templeton, Isobel M Poynten, Bridget G Haire, Catriona Ooi, Rosalind Foster, Anna McNulty, Andrew E Grulich, Iryna B Zablotska and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02206555 (Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02206555 phase4completednot on this map

Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project

TypeinterventionalSponsorKirby InstituteRan2014 to 2017Enrolled327ConditionsHIVArmsemtricitabine/tenofovir disoproxil fumarate
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Stefanie J VaccherThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Christopher GianacasThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
David J TempletonThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Isobel M PoyntenThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Bridget G HaireThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Catriona OoiWestern Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, NSW, Australia.
Rosalind FosterThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Anna McNultySydney Sexual Health Centre, Sydney, NSW, Australia.
Andrew E GrulichThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Iryna B ZablotskaThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
PRELUDE Study Team
UNSW Sydney · AUSydney Sexual Health Centre · AUUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe effectiveness of daily pre-exposure prophylaxis (PrEP) is well established. However, there has been increasing interest in non-daily dosing schedules among gay and bisexual men (GBM). This paper explores preferences for PrEP dosing schedules among GBM at baseline in the MATERIALS AND

methodsIndividuals at high-risk of HIV were enrolled in a free PrEP demonstration project in New South Wales, Australia, between November 2014 and April 2016. At baseline, they completed an online survey containing detailed behavioural, demographic, and attitudinal questions, including their ideal way to take PrEP: daily (one pill taken every day), event-driven (pills taken only around specific risk events), or periodic (daily dosing during periods of increased risk).

resultsOverall, 315 GBM (98% of study sample) provided a preferred PrEP dosing schedule at baseline. One-third of GBM expressed a preference for non-daily PrEP dosing: 20% for event-driven PrEP, and 14% for periodic PrEP. Individuals with a trade/vocational qualification were more likely to prefer periodic to daily PrEP [adjusted odds ratio (aOR) = 4.58, 95% confidence intervals (95% CI): (1.68, 12.49)], compared to individuals whose highest level of education was high school. Having an HIV-positive main regular partner was associated with strong preference for daily, compared to event-driven PrEP [aOR = 0.20, 95% CI: (0.04, 0.87)]. Participants who rated themselves better at taking medications were more likely to prefer daily over periodic PrEP [aOR = 0.39, 95% CI: (0.20, 0.76)]. DISCUSSION: Individuals' preferences for PrEP schedules are associated with demographic and behavioural factors that may impact on their ability to access health services and information about PrEP and patterns of HIV risk. At the time of data collection, there were limited data available about the efficacy of non-daily PrEP schedules, and clinicians only recommended daily PrEP to study participants. Further research investigating how behaviours and PrEP preferences change correspondingly over time is needed.

trial registrationClinicalTrials.gov NCT02206555. Registered 28 July 2014.

Indexed as

dosing preferencesevent-driven pre-exposure prophylaxisgay and bisexual menHIVnon-daily dosingperiodic pre-exposure prophylaxispre-exposure prophylaxis

Identifiers

PMID29326917
PMCPMC5736869
OpenAlexW2785308207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.